发布求助
文献互助 智能选刊 最新文献

Hematologia最新文献

筛选
英文 中文
Waldenström macroglobulinemia: diagnosis and treatment Waldenström巨球蛋白血症的诊断和治疗
Hematologia Pub Date : 2023-02-12 DOI: 10.5603/hcp.a2022.0014
K. Giannopoulos
{"title":"Waldenström macroglobulinemia: diagnosis and treatment","authors":"K. Giannopoulos","doi":"10.5603/hcp.a2022.0014","DOIUrl":"https://doi.org/10.5603/hcp.a2022.0014","url":null,"abstract":"Waldenström macroglobulinemia (WM), according to the 2017 World Health Organization classifi - cation, is defined as the co-occurrence of lymphoplasmacytic lymphoma involving the bone marrow with monoclonal gammopathy of the IgM class regardless of the concentration of monoclonal pro - tein. It is a rare lymphoproliferative disease with distinctive clinical features. Diagnostic character - istics in WM have changed significantly with the discovery of two molecular markers: MYD88 and CXCR4. The mutational status of these markers both affects clinical presentation and has shown therapeutic implications. The choice of treatment in WM is closely dependent on the patient’s age, risk of treatment-related neuropathy, and risk of immunosuppression or secondary malignancies. The therapeutic landscape has broadened in recent years, and the approvals of ibrutinib and zanu - brutinib represent a significant step forward toward better management of the disease","PeriodicalId":38988,"journal":{"name":"Hematologia","volume":"67 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78817583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recommendations for prevention of SARS-CoV-2 infection in immunocompromised patients 免疫功能低下患者预防SARS-CoV-2感染的建议
Hematologia Pub Date : 2023-01-31 DOI: 10.5603/hcp.a2022.0012
Krzysztof Tomasiewicz, Alicja Dębska-Ślizień, Magdalena Durlik, Krzysztof Giannopoulos, Iwona Hus, Piotr Rutkowski
{"title":"Recommendations for prevention of SARS-CoV-2 infection in immunocompromised patients","authors":"Krzysztof Tomasiewicz, Alicja Dębska-Ślizień, Magdalena Durlik, Krzysztof Giannopoulos, Iwona Hus, Piotr Rutkowski","doi":"10.5603/hcp.a2022.0012","DOIUrl":"https://doi.org/10.5603/hcp.a2022.0012","url":null,"abstract":"","PeriodicalId":38988,"journal":{"name":"Hematologia","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135306822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Haemophagocytic lymphohistiocytosis: case series. Serum ferritin level as an indicator of treatment effectiveness 噬血细胞淋巴组织细胞增多症:病例系列。血清铁蛋白水平作为治疗效果的指标
Hematologia Pub Date : 2023-01-13 DOI: 10.5603/hcp.a2022.0015
Daria Majowicz, K. Kostrzewa, Tomasz Gromek, B. Sokołowska, M. Hus
{"title":"Haemophagocytic lymphohistiocytosis: case series. Serum ferritin level as an indicator of treatment effectiveness","authors":"Daria Majowicz, K. Kostrzewa, Tomasz Gromek, B. Sokołowska, M. Hus","doi":"10.5603/hcp.a2022.0015","DOIUrl":"https://doi.org/10.5603/hcp.a2022.0015","url":null,"abstract":"","PeriodicalId":38988,"journal":{"name":"Hematologia","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73901723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis and treatment of immune thrombocytopenia in Poland 波兰免疫性血小板减少症的诊断和治疗
Hematologia Pub Date : 2022-10-20 DOI: 10.5603/hcp.a2022.0013
P. Malecki, S. Grosicki
{"title":"Diagnosis and treatment of immune thrombocytopenia in Poland","authors":"P. Malecki, S. Grosicki","doi":"10.5603/hcp.a2022.0013","DOIUrl":"https://doi.org/10.5603/hcp.a2022.0013","url":null,"abstract":"Immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by an isolated platelet count of less than 100,000/μL caused by destruction and reduced production of platelets. Systemic steroid therapy is a mainstay of first-line treatment; however, additional treatment lines are usually necessary due to the very high recurrence rate after therapy completion and steroid resistance. Standard treatment options for steroid resistance or steroid dependence include splenectomy, rituximab or thrombopoietin receptor agonists. The article presents current data on the diagnosics and therapy of ITP, considering the limited access to some forms of treatment in Poland","PeriodicalId":38988,"journal":{"name":"Hematologia","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75258273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimization of treatment of patients with plasma cell myeloma with high cytogenetic risk in Poland 波兰高细胞遗传风险浆细胞骨髓瘤患者的优化治疗
Hematologia Pub Date : 2022-10-20 DOI: 10.5603/hcp.a2022.0007
K. Giannopoulos, K. Jamroziak, T. Wróbel, D. Dytfeld
{"title":"Optimization of treatment of patients with plasma cell myeloma with high cytogenetic risk in Poland","authors":"K. Giannopoulos, K. Jamroziak, T. Wróbel, D. Dytfeld","doi":"10.5603/hcp.a2022.0007","DOIUrl":"https://doi.org/10.5603/hcp.a2022.0007","url":null,"abstract":"Plasma cell myeloma (PCM) is a hematologic malignancy that derives from mature B cells. The prognosis of patients with PCM is highly dependent on the presence of cytogenetic aberrations. Determination of cytogenetic risk enables informing patients about their prognosis and allows for individual choice of therapy. In Poland, cytogenetic risk assessment is a fully reimbursed procedure, and it is recommended to perform such an examination in every diagnosed patient. Therapy of patients with high cytogenetic risk should be planned with consideration of tandem autotrans-plantation of hematopoietic cells in eligible patients. In patients with refractory or relapsed PCM, treatment with ixazomib in combination with lenalidomide and dexamethasone appears to remove cytogenetic risk.","PeriodicalId":38988,"journal":{"name":"Hematologia","volume":"80 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82058893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Midostaurin added to standard therapy in FLT3-positive acute myeloid leukaemia treatment 在flt3阳性急性髓性白血病的标准治疗中加入米多夫林
Hematologia Pub Date : 2022-10-20 DOI: 10.5603/hcp.a2022.0011
A. Szczepaniak, Zuzanna Rzetelska
{"title":"Midostaurin added to standard therapy in FLT3-positive acute myeloid leukaemia treatment","authors":"A. Szczepaniak, Zuzanna Rzetelska","doi":"10.5603/hcp.a2022.0011","DOIUrl":"https://doi.org/10.5603/hcp.a2022.0011","url":null,"abstract":"Acute myeloid leukaemia (AML) is a complex disease with a dynamic course associated with a series of acquired and cumulative genetic changes. In recent years, significant advances have been made in the understanding of its pathogenesis. Moreover, diagnostic and therapeutic options have expanded. The current classifications consider cytogenetic and molecular disorders, including the presence of, among others, mutations within FMS-like tyrosine kinase 3 (FLT3) transmembrane tyrosine kinase, regulating the proliferation and differentiation of hematopoietic cells at an early development stage. FLT3 mutation is detected in approximately 30% of newly diagnosed AML cases and concerns mutations: internal tandem duplication (ITD) or tyrosine kinase domain (TKD) gene. The high ratio of FLT3-ITD mutation is associated with an unfavourable prognosis. It is recommended to includ patients in clinical trials due to insufficient standard therapy effects. The new AML treatment strategies include first-and second-generation tyrosine kinase inhibitors. Midostaurin, a non-specific kinase inhibitor, was approved in 2017 for treatment of patients with newly diagnosed FLT3-positive AML in combination with standard chemotherapy. The paper presents the experience of the Department of Haematology and Bone Marrow Transplantation in Poznan in the use of FLT3 tyrosine kinase inhibitors based on a case report of two patients with newly diagnosed AML.","PeriodicalId":38988,"journal":{"name":"Hematologia","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86480792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral manifestations of leukaemia: cooperation between dentist and haematologist 白血病的口腔表现:牙医与血液病专家的合作
Hematologia Pub Date : 2022-10-20 DOI: 10.5603/hcp.a2022.0009
Ewa Michalak, Agata Dudzik, Joanna Śręba, B. Kęsek, D. Darczuk
{"title":"Oral manifestations of leukaemia: cooperation between dentist and haematologist","authors":"Ewa Michalak, Agata Dudzik, Joanna Śręba, B. Kęsek, D. Darczuk","doi":"10.5603/hcp.a2022.0009","DOIUrl":"https://doi.org/10.5603/hcp.a2022.0009","url":null,"abstract":"Many systemic diseases can manifest in the oral mucosa. Leukaemia is the most common neoplastic disease of white blood cells. Common symptoms of leukaemia in the oral cavity include mucosa pallor, bleeding gums, gingival enlargement, ecchymosis, oral infections and ulcerations. A dentist should know how to recognize the first signs of leukaemia and may be responsible for a prompt referral to an adequate professional to improve patient outcomes. A dentist must participate in a patient’s process of treatment when the plan includes complex therapy of the oral cavity. In many cases, this procedure enables the implementation of appropriate therapy and the possibility of recovery and can even save the patient’s life. The study aimed to present the cooperation between the dentist and haematologist in the example of a 52-year-old female with oral symptoms of leukaemia.","PeriodicalId":38988,"journal":{"name":"Hematologia","volume":"57 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74971669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Eosinophilia caused by Toxocara canis infection 犬弓形虫感染所致嗜酸性粒细胞增多
Hematologia Pub Date : 2022-10-20 DOI: 10.5603/hcp.a2022.0010
Monika Kowalik, A. Gołos, J. Góra-tybor
{"title":"Eosinophilia caused by Toxocara canis infection","authors":"Monika Kowalik, A. Gołos, J. Góra-tybor","doi":"10.5603/hcp.a2022.0010","DOIUrl":"https://doi.org/10.5603/hcp.a2022.0010","url":null,"abstract":"Eosinophilia is defined as an absolute peripheral blood eosinophil count > 0.5 GL. Most often, its intensity is mild. Eosinophilia usually accompanies other diseases such as allergic, rheumatological, infectious, or oncological. The signs depend on the underlying diseases. After starting treatment of the underlying disease, the eosinophil count returns to the reference range. The diagnosis of eo-sinophilia starts by excluding the secondary causes. Clonal eosinophilia is a rare disease in which eosinophils are part of a tumor clone. The clonality is confirmed by molecular biology methods. The most common eosinophilic infiltration includes skin, lungs, and heart. The symptoms are not connected with a count of eosinophils in blood or bone marrow. The manifestation can be mild but also severe, life-threatening like venous thromboembolism. This article presents a case of 36-year-old man with eosinophilia caused by Toxocara canis infection manifested by systemic symptoms, erythroderma","PeriodicalId":38988,"journal":{"name":"Hematologia","volume":"115 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78997428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Wstęp
Hematologia Pub Date : 2021-01-07 DOI: 10.5603/hem.2020.0021
I. Hus
{"title":"Wstęp","authors":"I. Hus","doi":"10.5603/hem.2020.0021","DOIUrl":"https://doi.org/10.5603/hem.2020.0021","url":null,"abstract":"","PeriodicalId":38988,"journal":{"name":"Hematologia","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85467166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pytania testowwe
Hematologia Pub Date : 2020-12-27 DOI: 10.5603/hem.2020.0026
Pytania Testowe
{"title":"Pytania testowwe","authors":"Pytania Testowe","doi":"10.5603/hem.2020.0026","DOIUrl":"https://doi.org/10.5603/hem.2020.0026","url":null,"abstract":"","PeriodicalId":38988,"journal":{"name":"Hematologia","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78676129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信